Mylan eyes antiretroviral expansion in India after tender success
This article was originally published in Scrip
Executive Summary
Mylan, which recently kicked off commercial operations in India, starting with a portfolio of antiretroviral (ARV) drugs, appears keen to scale up in the HIV/AIDS segment at an opportune time.